RT Journal Article
SR Electronic
T1 Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000398
DO 10.1136/jitc-2019-000398
VO 8
IS 1
A1 Harriet M. Kluger
A1 Hussein A. Tawbi
A1 Maria L. Ascierto
A1 Michaela Bowden
A1 Margaret K. Callahan
A1 Edward Cha
A1 Helen X. Chen
A1 Charles G. Drake
A1 David M. Feltquate
A1 Robert L. Ferris
A1 James L. Gulley
A1 Shilpa Gupta
A1 Rachel W. Humphrey
A1 Theresa M. LaVallee
A1 Dung T. Le
A1 Vanessa M. Hubbard-Lucey
A1 Vassiliki A. Papadimitrakopoulou
A1 Michael A. Postow
A1 Eric H. Rubin
A1 Elad Sharon
A1 Janis M. Taube
A1 Suzanne L. Topalian
A1 Roberta Zappasodi
A1 Mario Sznol
A1 Ryan J. Sullivan
YR 2020
UL http://jitc.bmj.com/content/8/1/e000398.abstract
AB As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor as standard of care or in an investigational study. However, because of the kinetics and patterns of response to PD-1/PD-L1 blockade, and the lack of consistency in the clinical definitions of resistance to therapy, the design of clinical trials of new agents and interpretation of results remains an important challenge. To address this unmet need, the Society for Immunotherapy of Cancer convened a multistakeholder taskforce—consisting of experts in cancer immunotherapy from academia, industry, and government—to generate consensus clinical definitions for resistance to PD-(L)1 inhibitors in three distinct scenarios: primary resistance, secondary resistance, and progression after treatment discontinuation. The taskforce generated consensus on several key issues such as the timeframes that delineate each type of resistance, the necessity for confirmatory scans, and identified caveats for each specific resistance classification. The goal of this effort is to provide guidance for clinical trial design and to support analyses of emerging molecular and cellular data surrounding mechanisms of resistance.